AR037359A1 - Compuestos ligandos receptores de gastrina y colecistoquinina (cck), composicion farmaceutica y usos - Google Patents
Compuestos ligandos receptores de gastrina y colecistoquinina (cck), composicion farmaceutica y usosInfo
- Publication number
- AR037359A1 AR037359A1 ARP020104345A ARP020104345A AR037359A1 AR 037359 A1 AR037359 A1 AR 037359A1 AR P020104345 A ARP020104345 A AR P020104345A AR P020104345 A ARP020104345 A AR P020104345A AR 037359 A1 AR037359 A1 AR 037359A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carboxy
- amino
- aminocarbonyl
- thio
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 43
- -1 oxy, thio Chemical group 0.000 abstract 17
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 3
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 102100021022 Gastrin Human genes 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- PTXJQRBNKZRMEO-UHFFFAOYSA-N formamido formate Chemical compound O=CNOC=O PTXJQRBNKZRMEO-UHFFFAOYSA-N 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Uso de un compuesto de fórmula (1), en donde: R1 y R5 son independientemente H, alquilo C1-6, (alquil C1-6)oxi, tio, (alquil C1-6)tio, carboxi, carboxi(alquilo C1-6), formilo, (alquil C1-6)carbonilo, (alquilo C1-6)oxicarbonilo, (alquilo C1-6)carboniloxi, nitro, trihalometilo, hidroxi, hidroxi(alquilo C1-6), amino, (alquilo C1-6)amino, di(alquilo C1-6)amino, aminocarbonilo, halo, halo(alquiloC1-6), aminosulfonilo, (alquilo C1-6)sulfonilamino, (alquilo C1-6)aminocarbonilo, di (alquiloC1-6)aminocarbonilo, [N-Z]-(alquiloC1-6)carbonilamino, formiloxi, formanido, (alquilo C1-6)aminosulfonilo, di (alquilo C1-6)aminosulfonilo, [N-Z]-(alquilo C1-6)sulfonilamino o ciano; o R1 y R5 juntos forman un grupo metilenodioxi; R2 es un grupo hidrocarbilo C1-18 opcionalmente sustituido en donde hasta tres átomos de C pueden ser reemplazados opcionalmente por átomos de N, O y/o S; R3 es -(CR11R12)m-X-(CR13R14)p-R9; m es 0, 1 ó 2; p es 0, 1 ó 2; X es un enlace, -CR15=CR16-, -CsC-, C(O)NH, NHC(O), C(O)NMe, NMeC(O), C(O)O, NHC(O)NH, NHC(O)O, OC(O)NH, NH, O,CO, SO2, SO2NH, C(O)NHNH, o es un resto seleccionado del grupo de fórmula (2); R9 es H, alquilo C1-6; o fenilo, naftilo, piridilo, benzimidazolilo, indazolilo, quinolinilo, isoquinolinilo, tetrahidroisoquinolinilo, indolinilo, isoindolinilo, indolilo, isoindolilo o 2-piridonilo, todos opcionalmente sustituidos con 1, 2, ó 3 grupos seleccionados independientemente entre: -L-Q en donde: L es un enlace, o un grupo de la fórmula -(CR17R18)v-Y-CR17R18)w, en donde v y w son independientemente 0, 1, 2 ó 3, e Y es un enlace, -CR15=CR16-, tiazolilo, imidazolilo, oxazolilo, isoxazolilo, pirazolilo, isoxazolonilo, piperazinilo, piperidinilo, morfolinilo o pirrolidinilo; y Q es H; (alquilo C1-6)oxi, [N-Z]-(alquilo C1-6)oxi(alquilo C1-6)amino, tio, (alquilo C1-6)tio, carboxi(alquilo C1-6)tio, carboxi, carboxi(alquiloC1-6), carboxi(alquenilo C1-6), [N-Z]carboxi(alquiloC1-6)amino, carboxi(alquilo C1-6)oxi, formilo, (alquilo C1-6)carbonilo, (alquilo C1-6)-oxicarbonilo, (alquilo C1-6)carboniloxi, nitro, trihalometilo, hidroxi, amino, [N-Z](alquilo C1-6)amino, aminocarbonilo, (alquilo C1-6)aminocarbonilo, di(alquilo C1-6)aminocarbonilo, [N-Z](alquilo C1-6)carbonilamino, cicloalquilo C5-8, [N-Z](alquilo C1-6)carbonilo(alquiloC1-6amino, halo, halo(alquilo C1-6), sulfamoilo, [N-Z](alquilo C1-6)sulfonilamino, (alquilo C1-6)sulfonilaminocarbonilo, carboxi(alquilo C1-6)sulfonilo, carboxi(alquiloC1-6)sulfinilo, tetrazolilo, [N-Z]tetrazolilamino, ciano, amidino, amidinotio, SO3H, formiloxi, formamido, cicloalquilo C3-8, (alquilo C1-6)-sulfamoilo, di(alquilo C1-6)sulfamoilo, (alquilo C1-6)-carbonilaminosulfonilo o 5-oxo-2,5-dihidro-[1,2,4]oxadiazolilo; Z es H, alquilo C1-6, t-butoxicarbonilo, acetilo, benzoilo o bencilo; R4 es un grupo hidrocarbilo C1-18 opcionalmente sustituido en donde hasta tres átomos de C pueden ser reemplazados opcionalmente por átomos de N, O y/o S; y R11, R12, R13, R14, R15, R16, R17 y R18 son independientemente H o alquilo C1-3; o una sal farmacéuticamente aceptable del mismo; para la preparación de un medicamento para el tratamiento de trastornos relacionados con gastrina. Reivindicación 18: Una composición de acuerdo con la reivindicación 16 o 17, donde el inhibidor de la bomba de protones y el compuesto de fórmula (1) se encuentran cada uno en una cantidad que produce un efecto terapéuticamente beneficioso en pacientes que padecen trastornos gastrointestinales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0127262A GB0127262D0 (en) | 2001-11-13 | 2001-11-13 | Gastrin and cholecystokinin receptor ligands (VI) |
| GB0219051A GB0219051D0 (en) | 2002-08-15 | 2002-08-15 | Gastrin and cholecystokinin receptor ligands (V1-2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037359A1 true AR037359A1 (es) | 2004-11-03 |
Family
ID=26246762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104345A AR037359A1 (es) | 2001-11-13 | 2002-11-13 | Compuestos ligandos receptores de gastrina y colecistoquinina (cck), composicion farmaceutica y usos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060003993A1 (es) |
| EP (1) | EP1443934B1 (es) |
| JP (1) | JP2005513013A (es) |
| KR (1) | KR20050044852A (es) |
| CN (1) | CN100348196C (es) |
| AR (1) | AR037359A1 (es) |
| AT (1) | ATE293449T1 (es) |
| BR (1) | BR0213317A (es) |
| CA (1) | CA2466955A1 (es) |
| DE (1) | DE60203818T2 (es) |
| ES (1) | ES2240815T3 (es) |
| HU (1) | HUP0402068A3 (es) |
| IL (1) | IL161330A0 (es) |
| MX (1) | MXPA04003544A (es) |
| NO (1) | NO20042452L (es) |
| NZ (1) | NZ532213A (es) |
| PL (1) | PL369568A1 (es) |
| RU (1) | RU2304438C2 (es) |
| TW (1) | TW200303205A (es) |
| WO (1) | WO2003041714A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101533A1 (en) * | 2003-05-12 | 2004-11-25 | Janssen Pharmaceutica, N.V. | 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands |
| WO2005018640A1 (en) * | 2003-08-20 | 2005-03-03 | The Procter & Gamble Company | Kit for treatment of upper gastrointestinal tract conditions |
| WO2005074931A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations comprising (s) -pantoprazole |
| GB0425196D0 (en) * | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| EP1948624B1 (en) * | 2005-09-16 | 2013-10-23 | Janssen Pharmaceutica N.V. | Process for the preparation of benzo[e][1,2,4]triazepin-2-one derivatives |
| WO2007135417A1 (en) * | 2006-05-19 | 2007-11-29 | James Black Foundation | Benzotriazepinone derivatives |
| GB0610018D0 (en) * | 2006-05-19 | 2006-06-28 | James Black Foundation | Benzotriazepinone derivatives |
| US7863330B2 (en) | 2006-06-14 | 2011-01-04 | Rottapharm S.P.A. | Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders |
| RU2693484C1 (ru) | 2013-11-22 | 2019-07-03 | СиЭль БАЙОСАЕНСИЗ ЭлЭлСи | Антагонисты гастрина для лечения и профилактики остеопороза |
| GB201414116D0 (en) | 2014-08-08 | 2014-09-24 | Trio Medicines Ltd | Benzodiazepine derivatives |
| GB201513979D0 (en) | 2015-08-07 | 2015-09-23 | Trio Medicines Ltd | Synthesis of benzodiazepine derivatives |
| US11097031B2 (en) | 2016-08-01 | 2021-08-24 | The Procter & Gamble Company | Phase-stable, sprayable freshening compositions comprising suspended particles |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3176008A (en) * | 1962-09-11 | 1965-03-30 | American Home Prod | 5-phenyl-benzotriazepin-2-one compounds and their production |
| US5091381A (en) * | 1991-04-12 | 1992-02-25 | Biomeasure, Inc. | 2H-1,3,4-benzotriazepin-2-ones |
| WO1993012817A1 (en) * | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| US5378838A (en) * | 1993-01-13 | 1995-01-03 | Merck & Co., Inc. | Benzodiazepine cholecystokinin antagonists |
-
2002
- 2002-11-12 WO PCT/GB2002/005121 patent/WO2003041714A1/en not_active Ceased
- 2002-11-12 NZ NZ532213A patent/NZ532213A/en unknown
- 2002-11-12 EP EP02775003A patent/EP1443934B1/en not_active Expired - Lifetime
- 2002-11-12 KR KR1020047007006A patent/KR20050044852A/ko not_active Withdrawn
- 2002-11-12 CN CNB028223403A patent/CN100348196C/zh not_active Expired - Fee Related
- 2002-11-12 IL IL16133002A patent/IL161330A0/xx unknown
- 2002-11-12 JP JP2003543601A patent/JP2005513013A/ja active Pending
- 2002-11-12 BR BR0213317-2A patent/BR0213317A/pt not_active Application Discontinuation
- 2002-11-12 HU HU0402068A patent/HUP0402068A3/hu unknown
- 2002-11-12 AT AT02775003T patent/ATE293449T1/de not_active IP Right Cessation
- 2002-11-12 CA CA002466955A patent/CA2466955A1/en not_active Abandoned
- 2002-11-12 ES ES02775003T patent/ES2240815T3/es not_active Expired - Lifetime
- 2002-11-12 DE DE60203818T patent/DE60203818T2/de not_active Expired - Fee Related
- 2002-11-12 RU RU2004117880/15A patent/RU2304438C2/ru not_active IP Right Cessation
- 2002-11-12 US US10/495,464 patent/US20060003993A1/en not_active Abandoned
- 2002-11-12 MX MXPA04003544A patent/MXPA04003544A/es unknown
- 2002-11-12 PL PL02369568A patent/PL369568A1/xx not_active Application Discontinuation
- 2002-11-13 AR ARP020104345A patent/AR037359A1/es unknown
- 2002-11-13 TW TW091133267A patent/TW200303205A/zh unknown
-
2004
- 2004-06-11 NO NO20042452A patent/NO20042452L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60203818T2 (de) | 2006-01-26 |
| CN1585643A (zh) | 2005-02-23 |
| ATE293449T1 (de) | 2005-05-15 |
| HUP0402068A2 (hu) | 2005-02-28 |
| BR0213317A (pt) | 2004-10-13 |
| US20060003993A1 (en) | 2006-01-05 |
| IL161330A0 (en) | 2004-09-27 |
| RU2004117880A (ru) | 2005-04-20 |
| KR20050044852A (ko) | 2005-05-13 |
| ES2240815T3 (es) | 2005-10-16 |
| JP2005513013A (ja) | 2005-05-12 |
| CA2466955A1 (en) | 2003-05-22 |
| WO2003041714A1 (en) | 2003-05-22 |
| DE60203818D1 (de) | 2005-05-25 |
| NO20042452L (no) | 2004-08-12 |
| PL369568A1 (en) | 2005-05-02 |
| TW200303205A (en) | 2003-09-01 |
| RU2304438C2 (ru) | 2007-08-20 |
| HUP0402068A3 (en) | 2005-09-28 |
| CN100348196C (zh) | 2007-11-14 |
| AU2002341218B2 (en) | 2007-03-15 |
| EP1443934B1 (en) | 2005-04-20 |
| MXPA04003544A (es) | 2004-07-22 |
| NZ532213A (en) | 2006-12-22 |
| EP1443934A1 (en) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037359A1 (es) | Compuestos ligandos receptores de gastrina y colecistoquinina (cck), composicion farmaceutica y usos | |
| AU2021213258B2 (en) | Compounds and uses thereof | |
| ES2817785T3 (es) | Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de la -lactamasa | |
| ES2349110T5 (es) | Inhibidores de IAP derivados de pirrolidina | |
| ES2200243T3 (es) | Inhibidores de tipo sulfonamida de la aspartil-proteasa de vih. | |
| RU2505540C2 (ru) | Антивирусные соединения | |
| ES2524449T3 (es) | Inhibidores de IAP | |
| ES2305338T3 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6. | |
| ES2908224T3 (es) | Derivados de dolastatina 10 y auristatinas | |
| US20120015974A1 (en) | Imidazopyridine inhibitors of iap | |
| AR035325A1 (es) | Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento | |
| JP2021152063A5 (es) | ||
| KR930004276A (ko) | 치환된 헤테로사이클류 | |
| RU2005123807A (ru) | Тетрагидро-4н-пиридо[1,2-а]пиримидины и родственные соединения, полезные в качестве ингибиторов вич-интегразы | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| WO2006073167A1 (ja) | ピロリジン誘導体 | |
| RU2005105053A (ru) | Новые производные пиперидина для применения в лечении болезненных состояний, опосредованных хемокинами | |
| JP2003500404A5 (es) | ||
| CA2150550A1 (en) | Fibrinogen receptor antagonists | |
| CA2481369A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| RU96120088A (ru) | Антитромботические агенты | |
| AR042648A1 (es) | Derivados de pirazol como inhibidores del factor xa ******* no publicar ********** desistimiento voluntario ********** pasar a alejandra villoldo *********** | |
| US20110218211A1 (en) | Azaindole inhibitors of iap | |
| ES2849998T3 (es) | Compuestos heterocíclicos y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |